04Jun/13

Novartis phase III trial shows Afinitor delays tumour growth in HER2 positive … – pharmabiz.com

June 4, 2013Immunosuppressive Drugsadmin

Novartis phase III trial shows Afinitor delays tumour growth in HER2 positive …
pharmabiz.com
Novartis has presented results from a pivotal phase III trial of a treatment regimen including Afinitor (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior …
Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor …PR Newswire (press release)
Novartis reports positive breast cancer data for AfinitorZenopa
NOVARTIS AG : pivotal Phase III trial shows Afinitor® significantly delays …4-traders (press release)

all 5 news articles »

03Jun/13

The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for … – 7thSpace Interactive (press release)

June 3, 2013Immunosuppressive Drugsadmin

The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for …7thSpace Interactive (press release)We further hypothesized that treatment with cyclosporine A, a Pgp1 inhibitor, would render cells more sensitive to treatment with corticost…

03Jun/13

Novartis pivotal Phase III trial shows AfinitorÂ® significantly delays tumor … – PharmiWeb.com (press release)

June 3, 2013Immunosuppressive Drugsadmin

Novartis pivotal Phase III trial shows AfinitorÂ® significantly delays tumor …
PharmiWeb.com (press release)
Novartis today presented results from a pivotal Phase III trial of a treatment regimen including AfinitorÂ® (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior …
Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor …SYS-CON Media (press release)
NOVARTIS AG : pivotal Phase III trial shows Afinitor® significantly delays …4-traders (press release)

all 4 news articles »

02Jun/13

Exelixis begins phase 3 trial of cabozantinib in metastatic renal cell … – pharmabiz.com

June 2, 2013Immunosuppressive Drugsadmin

Exelixis begins phase 3 trial of cabozantinib in metastatic renal cell …pharmabiz.comExelixis, Inc, a biotechnology company committed to developing small molecule therapies for the treatment of cancer, has initiated METEOR, a phase 3 pivotal trial co…

02Jun/13

Highlights from ASCO: Bayer's Nexavar; Novartis' Afinitor; and Amgen's … – The Pharma Letter

June 2, 2013Immunosuppressive Drugsadmin

Highlights from ASCO: Bayer’s Nexavar; Novartis’ Afinitor; and Amgen’s …
The Pharma Letter
Also at ASCO yesterday, Swiss drug major Novartis (NOVN: VX) presented results from a pivotal Phase III trial of a treatment regimen including Afinitor (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) …

and more »

02Jun/13

Novartis pivotal Phase III trial shows Afinitor significantly delays tumor … – MarketWatch (press release)

June 2, 2013Immunosuppressive Drugsadmin

Novartis pivotal Phase III trial shows Afinitor significantly delays tumor …
MarketWatch (press release)
EAST HANOVER, N.J., June 2, 2013 /PRNewswire via COMTEX/ — Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor� (everolimus) tablets in women with human epidermal growth factor receptor-2 positive …

and more »

01Jun/13

When nature hurts: How to treat some of the common injuries of summer – PennLive.com

June 1, 2013Immunosuppressive Drugsadmin

When nature hurts: How to treat some of the common injuries of summer
PennLive.com
OTC remedy: Topical steroids such as hydrocortisone and oral antihistamines such as diphenhydramine. When to see the doctor: Call 911 or head to your nearest emergency department after a sting if you are allergic to bee stings. “Anaphylaxis occurs in …

01Jun/13

Dr. O'Shaughnessy on Everolimus in Breast Cancer – OncLive

June 1, 2013Immunosuppressive Drugsadmin

Dr. O’Shaughnessy on Everolimus in Breast Cancer
OncLive
Joyce A. O’Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center; Texas Oncology, PA/US Oncology, Dallas, Texas, describes potentially practice changing findings from the BOLERO-3 trial.

and more »

31May/13

Augmentin implicated in drug-induced liver injury – Family Practice News Digital Network

May 31, 2013Immunosuppressive Drugsadmin

Augmentin implicated in drug-induced liver injury
Family Practice News Digital Network
By tying the injury to Iceland’s prescription drug database, that meant an incidence of DILI among outpatients of 1 per 133 filled azathioprine prescriptions and 1 in 2,350 amoxicillin-clavulanate users; among inpatients, the incidence of injury …

31May/13

Exelixis (EXEL) Commences Phase 3 of Cabozantinib vs. Everolimus in MRCC … – StreetInsider.com (subscription)

May 31, 2013Immunosuppressive Drugsadmin

Exelixis (EXEL) Commences Phase 3 of Cabozantinib vs. Everolimus in MRCC …StreetInsider.com (subscription)Exelixis, Inc. (Nasdaq: EXEL) has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic ren…

Category Archives: Immunosuppressive Drugs